OmniAb and PepGen 2025 Results Clouded by FDA Hold on Freedom2 Trial
OmniAb and PepGen reported full-year 2025 results, highlighting a divergence between platform-based stability and clinical-stage volatility. While OmniAb expanded its royalty-bearing portfolio, PepGen faced a significant setback with a partial FDA clinical hold on its Freedom2 trial.